Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT00900263 Completed - Multiple Myeloma Clinical Trials

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

Start date: June 2002
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur in DNA and identify biomarkers related to these diseases. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood and bone marrow samples from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma.

NCT ID: NCT00900055 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Start date: June 1975
Phase:
Study type: Observational

RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of blood cancers. PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders, or myeloma.

NCT ID: NCT00899847 Completed - Multiple Myeloma Clinical Trials

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Start date: May 2009
Phase: Phase 2
Study type: Interventional

To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.

NCT ID: NCT00899080 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide

Start date: July 4, 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood samples from patients with multiple myeloma who were treated with thalidomide or lenalidomide.

NCT ID: NCT00898066 Completed - Lymphoma Clinical Trials

S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease

Start date: September 2005
Phase: N/A
Study type: Observational

RATIONALE: Studying the chromosomes in samples of bone marrow and blood in the laboratory from patients with cancer or other blood diseases may help doctors learn more about the disease. PURPOSE: This laboratory study is analyzing chromosomes in patients with newly diagnosed multiple myeloma or other blood disease.

NCT ID: NCT00898040 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Study of DNA Samples From Patients With Multiple Myeloma

Start date: July 6, 2006
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at DNA samples from patients with multiple myeloma.

NCT ID: NCT00891592 Completed - Multiple Myeloma Clinical Trials

Umbilical Cord Blood Transplant for Hematological Malignancies

UCB
Start date: January 2009
Phase: Phase 1
Study type: Interventional

This protocol will enroll subjects with advanced hematologic malignancies who do not have a suitable related or unrelated donor to undergo a Stem Cell Transplant. In this study, subjects will undergo a Stem Cell Transplant using Cord Blood. Part of the cord blood will be used for the Stem Cell Transplant and part of the cord blood will be sent to a laboratory in order to grow the T cells (from the cord blood) and increase the activity of the cord blood T cells. The purpose of this part of the study is to see if it is safe to give study subjects activated T cells made from a small portion of their donor UCB unit immediately after the UCB transplant. Activated T cells have been used safely in stem cell transplantation studies in the past, but they have never been studied UCB transplantation.

NCT ID: NCT00891384 Completed - Multiple Myeloma Clinical Trials

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Start date: April 1, 2009
Phase: Phase 3
Study type: Interventional

This trial is a randomised, parallel-group, multicenter phase III study for maintenance therapy with lenalidomide in patients with multiple myeloma who were treated with high-dose therapy and autologous stem cell transplantation as first line therapy.

NCT ID: NCT00891137 Completed - Multiple Myeloma Clinical Trials

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Start date: April 2009
Phase: Phase 1
Study type: Interventional

Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic cancer. In this study, the safety and tolerability of CLT-008 administered 24 hours after an umbilical cord blood transplant will be determined by monitoring for adverse reactions, neutrophil and platelet recovery, hematopoietic chimerism, graft-versus-host disease (GVHD), and infections.

NCT ID: NCT00890747 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Start date: August 2009
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of sunitinib malate in treating human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral therapy. Sunitinib malate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.